Method for evaluating or assisting in evaluating hepatocytes and marker used by method

By detecting the expression level of SREBP2 protein or its encoding gene, the problem of evaluation of liver aging is solved, and biomarkers of liver aging are provided to help predict and prevent related diseases, and effective evaluation and prevention of liver aging is achieved.

CN118932039APending Publication Date: 2024-11-12INST OF ZOOLOGY CHINESE ACAD OF SCI +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310534654.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-12
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art is difficult to effectively evaluate and predict liver aging and its related diseases, and the lack of effective biomarkers and evaluation methods has led to limited development of prevention and treatment strategies for liver aging and related diseases.

Method used

By detecting the expression level of SREBP2 protein or its encoding gene, using specific antibodies or quantitative PCR detection systems, we can evaluate the aging degree and functional status of hepatocytes, distinguish aging from young hepatocytes, and develop the following methods for evaluating liver aging-related diseases Kits and animal models.

Benefits of technology

Successfully distinguishes and evaluates the aging degree of liver cells, provides potential biomarkers of liver aging, helps predict and prevent liver aging and related diseases, such as fatty liver, liver fibrosis and liver cancer, and provides important theoretical basis and application value. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0004225669000000011
    Figure HDA0004225669000000011
  • Figure HDA0004225669000000012
    Figure HDA0004225669000000012
  • Figure HDA0004225669000000013
    Figure HDA0004225669000000013
Patent Text Reader

Abstract

The invention discloses a method for evaluating or assisting in evaluating hepatocytes and a marker used by the method. The invention provides any one of the following applications of a substance for detecting the expression of the SREBP2 protein or the coding gene of the SREBP2 protein: preparing a product for evaluating or assisting in evaluating the aging degree of the liver; or preparing a product for evaluating or assisting in evaluating the aging degree of the hepatocytes; or preparing a product for evaluating or assisting in evaluating the functional state of the hepatocytes; or preparing a product for distinguishing or assisting in distinguishing the aged hepatocytes from the young hepatocytes; or preparing a product for evaluating or assisting in evaluating liver aging related diseases or liver cell aging related diseases or aging related liver diseases. Experiments prove that SREBP2 can be used as a marker for evaluating human hepatocyte senescence, and the marker can be used for evaluating liver senescence, hepatocyte senescence, diseases related to hepatocyte senescence and various liver diseases related to aging. The method has an important application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and in particular relates to a method for evaluating or assisting in evaluating liver cells and a marker used therein. Background Art

[0002] As the largest solid and metabolic organ in the body, the liver is crucial to maintaining the body's homeostatic balance. It performs various physiological functions, such as regulating energy metabolism, molecular biosynthesis, and removing foreign bodies. Many external and internal factors can lead to liver aging. The liver will undergo a series of characteristic changes with the aging process, including volume reduction, decreased blood flow, increased inflammatory response and fibrosis, accumulation of senescent cells, and gradual loss of organ function, which will increase susceptibility to related diseases and cause a great economic and social burden. Therefore, in-depth analysis of the cellular and molecular mechanisms of liver aging can explore the key targets of liver aging, and then discover potential biomarkers that can predict liver or body aging and related diseases, laying a key theoretical foundation for the development of prevention and treatment strategies for liver aging and related diseases. Summary of the invention

[0003] The purpose of the present invention is to provide a method for evaluating or assisting in the evaluation of hepatocytes and markers used therein, so as to further study liver aging, diseases related to hepatocyte aging, and various liver diseases related to aging.

[0004] In a first aspect, the present invention provides a method for detecting the expression of SREBP2 protein or its encoding gene for use in any of the following:

[0005] a1) Preparation of products for assessing or assisting in assessing the degree of liver aging;

[0006] a2) preparing products for evaluating or assisting in evaluating the degree of hepatocyte senescence;

[0007] a3) Preparation of products that assess or assist in assessing the functional status of hepatocytes;

[0008] a4) preparing products that differentiate or assist in differentiating between senescent hepatocytes and young hepatocytes;

[0009] a5) Preparation of products for evaluating or assisting in the evaluation of liver aging-related diseases, hepatocyte aging-related diseases, or age-related liver diseases.

[0010] In the above application, the substance for detecting the expression of SREBP2 protein or its encoding gene is a substance that specifically binds to SREBP2 protein or its encoding gene.

[0011] The substance that binds to the SREBP2 protein mentioned above may be a monoclonal antibody or a polyclonal antibody against SREBP2; the substance that specifically binds to the SREBP2 encoding gene (SREBP2 gene) may be a system for detecting the expression of the SREBP2 gene by quantitative PCR, further specifically including a specific primer pair for PCR amplification of the SREBP2 encoding gene; in the embodiment of the present invention, it is specifically as follows:

[0012] SREBP2 forward(monkey)AACGGTCATTCACCCAGGTC

[0013] SREBP2 reverse(monkey)GGCTGAAGAATAGGAGTGTGCC

[0014] or,

[0015] SREBP2 forward(human)AACGGTCATTCACCCAGGTC

[0016] SREBP2 reverse(human)GGCTGAAGAATAGGAGTGTGCC

[0017] In the above application, the test sample of the product can be hepatocytes, or can be a tissue sample separated from primate or human liver tissue, its paraffin section or its frozen section.

[0018] In the above applications, the evaluation or auxiliary evaluation of the degree of hepatocyte aging or the evaluation or auxiliary evaluation of the functional status of hepatocytes is specifically as follows (S1) or (S2) or (S3) or (S4):

[0019] (S1) detecting the expression level of a target protein in a hepatocyte, wherein the target protein is SREBP2, and then making the following judgment: if the expression level of the target protein is higher than that of a control group, the cell function state of the hepatocyte is or may be damaged; if the expression level of the target protein is lower than that of the control group, the cell function state of the hepatocyte is or may be better maintained;

[0020] (S2) detecting the expression level of transcripts containing the target gene in the hepatocytes, where the target gene is the SREBP2 gene, and then making the following judgment: if the expression level of the transcripts containing the target gene is higher than that of the control group, the cell function state of the hepatocytes is or may be damaged; if the expression level of the transcripts containing the target gene is lower than that of the control group, the cell function state of the hepatocytes is or may be better maintained.

[0021] The control group is a young sample with a known biological age, or a sample with a known undamaged liver cell function.

[0022] Examples of the younger known biological ages are as follows: the average age of young crab-eating macaques is 5 years old, and the average age of old crab-eating macaques is 19 years old; their corresponding human ages are approximately: 18 years young and 68 years old.

[0023] In the embodiment of the present invention, the following is taken as an example: the hepatocytes are human hepatocytes overexpressing SREBP2 through lentivirus infection, and the control group is human hepatocytes without SREBP2 introduced.

[0024] (S3) comparing the expression levels of the target gene in the two liver cell samples to be tested, where the target gene is SREBP2; then making the following judgment: the aging degree of the liver cell sample to be tested with a high expression level of the target gene SREBP2 is higher or candidate higher than the aging degree of the liver cell sample to be tested with a low expression level of the target gene SREBP2; in the embodiment of the present invention, primate liver cells are taken as an example, specifically crab-eating macaques.

[0025] (S4) comparing the expression levels of the target protein in the two liver cell samples to be tested, the target protein being SREBP2; and then making the following judgment: the aging degree of the liver cell sample to be tested with a high expression level of the target protein SREBP2 is higher or candidate higher than the aging degree of the liver cell sample to be tested with a low expression level of the target protein SREBP2. In the embodiment of the present invention, primate liver cells are taken as an example, specifically cynomolgus monkeys.

[0026] In the above application, the distinction between senescent hepatocytes and young hepatocytes is as follows (R1) or (R2):

[0027] (R1) Compare the expression levels of the target protein in the hepatocytes to be tested and in the young hepatocytes, where the target protein is SREBP2; then make the following judgment: if the expression level of the target protein in the hepatocytes to be tested is higher than that in the young hepatocytes, the hepatocytes to be tested are or are suspected to be aging hepatocytes; otherwise, they are or are suspected to be young hepatocytes.

[0028] (R2) Compare the expression levels of the target gene in the tested liver cells and the young liver cells, the target gene is the SREBP2 gene; then make the following judgment: if the expression level of the target gene in the tested liver cells is higher than that in the young liver cells, the tested liver cells are or are suspected to be aging liver cells; otherwise, they are or are suspected to be young liver cells.

[0029] Any of the above-mentioned aged hepatocytes refers to the hepatocytes of the liver of an old animal or a human. Any of the above-mentioned young hepatocytes refers to the hepatocytes of the liver of a young animal or a human. In the embodiments of the present invention, the following is taken as an example: the average age of cynomolgus monkeys is: the average age of young cynomolgus monkeys is 5 years old, and the average age of old cynomolgus monkeys is 19 years old; their corresponding human ages are approximately: young 18 years old, old 68 years old.

[0030] In a second aspect, the present invention provides the use of SREBP2 protein or its encoding gene as a marker in any of the following:

[0031] a1) Preparation of products for assessing or assisting in assessing the degree of liver aging;

[0032] a2) preparing products for evaluating or assisting in evaluating the degree of hepatocyte senescence;

[0033] a3) Prepare or develop products that assess or assist in assessing the functional status of hepatocytes;

[0034] a4) Prepare or develop products that differentiate or assist in differentiating between senescent hepatocytes and young hepatocytes;

[0035] a5) Prepare or develop products for evaluating or assisting in the evaluation of liver aging-related diseases, hepatocellular aging-related diseases, or age-related liver diseases.

[0036] In a third aspect, the present invention provides a kit, comprising the substance for detecting the expression of SREBP2 protein or its encoding gene as described in the first aspect;

[0037] The kit has any of the following functions:

[0038] b1) Assess or assist in assessing the degree of liver aging;

[0039] b2) Evaluate or assist in evaluating the degree of hepatocyte senescence;

[0040] b3) Evaluate or assist in evaluating the functional status of hepatocytes;

[0041] b4) distinguishing or assisting in distinguishing senescent hepatocytes from young hepatocytes;

[0042] b5) Evaluate or assist in the evaluation of liver aging-related diseases, hepatocellular aging-related diseases, or age-related liver diseases.

[0043] In a fourth aspect, the present invention provides the use of a SREBP2 encoding gene or a SREBP2 protein.

[0044] The present invention provides the use of a SREBP2 encoding gene or a SREBP2 protein in any of the following:

[0045] c1) Preparation of products that promote or induce liver aging;

[0046] c2) preparing products that promote or induce hepatocyte senescence;

[0047] c3) Preparation of products that promote or induce liver cell function damage;

[0048] c4) preparing products that promote liver damage.

[0049] Alternatively, the present invention provides the use of a SREBP2 encoding gene or a SREBP2 protein in any of the following:

[0050] d1) Application in the preparation of animal models of liver aging;

[0051] d2) Application in the preparation of animal models of hepatocyte aging;

[0052] d3) Application in the preparation of animal models of hepatocyte function damage.

[0053] In a fifth aspect, the present invention provides a method for preparing an animal model of liver aging, hepatocyte aging, or hepatocyte function damage, comprising the following steps: introducing the SREBP2 gene into animal cells to obtain an animal model of liver aging, hepatocyte aging, or hepatocyte function damage.

[0054] In the above, the liver is derived from animals or humans;

[0055] The hepatocytes are derived from animals or humans;

[0056] Furthermore, the hepatocytes are derived from primates.

[0057] The inventors of the present invention have found that SREBP2 protein or its encoding gene can be used as a marker for evaluating liver aging by constructing and analyzing a primate liver sequencing library and performing Western blot and fluorescence quantitative PCR detection. SREBP2 protein or its encoding gene can be used as a marker to distinguish aging hepatocytes from young hepatocytes. The marker can be used to evaluate liver aging, hepatocyte aging, hepatocyte aging-related diseases, and various liver diseases related to aging, such as fatty liver, liver fibrosis, cirrhosis, and liver cancer. In addition, intervention or treatment can be performed by using an inhibitor of SREBP2. Therefore, the gene can be used to construct an animal liver aging model after overexpression. The present invention has important application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0058] Figure 1 Schematic diagram of single-cell nucleus sequencing of cynomolgus macaque liver.

[0059] Figure 2 The number of differentially expressed genes in different cell types in the liver of young and old cynomolgus monkeys was analyzed for bioinformatics.

[0060] Figure 3 To bioinformatically analyze the sensitivity of individual cell types in the liver of young and old cynomolgus monkeys to aging responses.

[0061] Figure 4 Analysis of transcription factor regulatory network in hepatocytes.

[0062] Figure 5The expression of SREBP2 gene in the liver of young and old cynomolgus monkeys.

[0063] Figure 6 The expression of SREBP2 protein in the liver of young and old cynomolgus monkeys.

[0064] Figure 7 The expression of SREBP2 gene and hepatocyte function-related genes in human primary hepatocytes overexpressing SREBP2.

[0065] Figure 8 The expression of senescence-associated β-galactosidase (SA-β-gal) in human primary hepatocytes overexpressing SREBP2. DETAILED DESCRIPTION

[0066] The following examples are provided to facilitate a better understanding of the present invention, but are not intended to limit the present invention.

[0067] The experimental methods in the following examples are all conventional methods unless otherwise specified.

[0068] Unless otherwise specified, the test materials used in the following examples were purchased from conventional biochemical reagent stores.

[0069] Human primary hepatocytes, human primary hepatocyte recovery medium, human primary hepatocyte plating medium and human primary hepatocyte maintenance medium were all purchased from Lonza, with catalog numbers HUCPI, MCHT50, MP100 and CC-3198, respectively; Superasin with catalog number AM2694 was purchased from Thermo Fisher; RNaseIn with catalog number N2615 was purchased from Promega; goat anti-rabbit secondary antibody, goat anti-mouse secondary antibody and PBS were all purchased from Zhongshan Golden Bridge, with catalog numbers ZB-2301, ZB-2305 and ZLI-9062, respectively; PVDF membrane was purchased from Millipore with catalog number ISEQ00010; GoScript reverse transcription kit was purchased from PROMEGA with catalog number A5001; PrimerSTAR was purchased from Takara with catalog number R044A; BCA protein quantification kit was purchased from Dingguo Changsheng with catalog number BCA-02.

[0070] The experiments on non-human primates cynomolgus monkeys in the following examples have been approved by the Institute of Zoology, Chinese Academy of Sciences for ethics.

[0071] Example 1: Obtaining a single-cell nuclear sequencing library from cynomolgus monkey liver

[0072] Schematic diagram of the construction and analysis of the cynomolgus monkey liver single-cell nuclear sequencing library is shown in Figure 1 .

[0073] 1. Preparation of single cell nuclear suspension from cynomolgus monkey liver

[0074] The liver tissues were obtained from 8 young cynomolgus monkeys (4-6 years old) and 8 old cynomolgus monkeys (18-21 years old). All animals used were confirmed to have no clinical disease, experimental experience or pregnancy history.

[0075] Obtain a suspension of liver cell nuclei from each individual. The specific steps are as follows:

[0076] 1. When isolating liver tissue samples, the cynomolgus monkeys were first fully anesthetized and perfused with phosphate buffer, and then the liver tissue was completely separated according to the tissue anatomy and the attached fat tissue was removed. After taking pictures and weighing, the liver tissue was cut into almost uniform sizes and quickly cryopreserved in liquid nitrogen.

[0077] 2. Take out the tissue samples frozen in liquid nitrogen, separate soybean-sized tissue blocks, grind them into uniform powder with steel balls and tissue grinder, add 1mL HOMO buffer, shake and mix, and let stand on ice for 5min. After filtering with a cell sieve with a pore size of 40μm, centrifuge at 3000g for 8min at 4℃. Discard the supernatant, add 500μL of 0.3% BSA solution to resuspend, blow gently, then filter again with a flow tube, mix gently and transfer to ice to stand. Cell nuclei were sorted by flow cytometry to obtain single cell nuclear suspensions of young and old cynomolgus monkey livers.

[0078] 2. Sequencing Library Construction and Sequencing of Cynomolgus Monkey Liver Single Cell Nuclear Suspension

[0079] The single cell nuclear suspension of the liver of young cynomolgus monkeys and the single cell nuclear suspension of the liver of old cynomolgus monkeys were used to construct libraries according to the reagent instructions of 10×Genomic Company. The capture amount was set to 6000 cell nuclei for each sample. The cDNA sample was first obtained by reverse transcription, and then amplified for 12 cycles. Then, after passing the quality control, the Chromium Single Cell3'GEM Library and Gel Bead Kit v3 was used to build the library, and the sequencing was completed by the NovaSeq 6000 sequencing platform to obtain the sequencing results of the old and young groups.

[0080] Example 2. Acquisition and detection of molecular markers of aging cynomolgus monkey hepatocytes

[0081] 1. Obtaining molecular markers of aging cynomolgus monkey hepatocytes through bioinformatics analysis

[0082] 1. Analysis of differentially expressed genes in various cell types in the liver of young and old cynomolgus monkeys.

[0083] Seurat function "FindMarkers" and Wilcoxon sign-rank test were used to calculate age-related differentially expressed genes in the sequencing data of the old and young groups (Aged / Young). Genes with |'avg_logFC'|>0.25 and 'p_val_adj'<0.05 were defined as aging-related differentially expressed genes (DEGs).

[0084] The results are as follows Figure 2 As shown, during the aging process, there are large differences in the number of differentially expressed genes in different cell types, among which liver cells have the largest number of differentially expressed genes.

[0085] 2. Bioinformatics analysis of the sensitivity of each cell type to aging response

[0086] The sensitivity score of each cell type to senescence was calculated by the R package Augur (version 1.0.3) using the function 'calculate_auc' with default parameters.

[0087] The results are as follows Figure 3 As shown, it can be seen that hepatocytes are the cell type in the liver that is most strongly affected by aging.

[0088] 3. Analysis of the mutual regulatory network of transcription factors.

[0089] The upstream transcriptional regulatory network of age-related differentially expressed genes was analyzed using the R packages GENIE3 (version 1.12.0) and RcisTarget (version 1.10.0) of the R package SCENIC (version 1.2.4) with default parameters.

[0090] The results are as follows Figure 4 As shown, multiple transcription factors are in the core regulatory position in hepatocytes of aging liver, among which SREBP2 is particularly obvious and most widely regulates aging-related differential genes in hepatocytes. Therefore, SREBP2 may be a marker of hepatocyte aging.

[0091] 2. Real-time fluorescence quantitative PCR and Western blot detection

[0092] 1. Real-time fluorescence quantitative PCR

[0093] The genomic DNA from the livers of 8 young cynomolgus monkeys (4-6 years old, denoted as the young group in the figure) and 8 old cynomolgus monkeys (18-21 years old, denoted as the old group in the figure) was extracted as a template, and real-time fluorescence quantitative PCR was performed using the following cynomolgus monkey SREBP2 gene primers:

[0094] 1) The primer sequence of the human target gene SREBP2 was searched through PrimerBank. The primers used for the cynomolgus monkey samples needed to align the human primer sequence with the cynomolgus monkey genome and replace the inconsistent bases before use.

[0095] The primer sequences of the cynomolgus monkey SREBP2 gene are as follows:

[0096] SREBP2 forward(monkey)AACGGTCATTCACCCAGGTC

[0097] SREBP2 reverse(monkey)GGCTGAAGAATAGGAGTGTGCC

[0098] The primers were dissolved in ddH2O to a concentration of 10 μM and the cDNA template was diluted 10-fold for later use.

[0099] 2) Adoption qPCR Mix was used for real-time fluorescence quantitative PCR reaction.

[0100] 3) After the above PCR reaction solution is fully mixed, it is placed in a PCR instrument for three-step fragment amplification.

[0101] The results are as follows Figure 5 As shown, it was shown that the transcript level of SREBP2 gene was increased in the liver of old cynomolgus monkeys compared with that in the liver of young cynomolgus monkeys.

[0102] 2. Western blot

[0103] 1) Soybean-sized liquid nitrogen frozen liver tissues of 8 young cynomolgus monkeys (4-6 years old) and 8 old cynomolgus monkeys (18-21 years old) were taken and ground into a uniform powder using a tissue grinder. Then 500 μL of 2×SDS protein lysis buffer was added, and the mixture was shaken and mixed thoroughly. The mixture was lysed on ice for 20 minutes. The protein was then denatured by heating in a 105°C metal bath for 10 minutes, and the supernatant was collected after centrifugation.

[0104] 2) Use the BCA protein quantification kit to determine the protein concentration. Set up 2 replicates for each sample. Perform subsequent operations according to the kit instructions and prepare gel samples according to the protein concentration.

[0105] 3) Specific steps of protein immunoblotting experiment

[0106] a) Electrophoresis: Accurately install the prepared polyacrylamide gel plate into the electrophoresis tank, add an appropriate amount of electrophoresis buffer and observe whether there is obvious leakage, then add the prepared protein sample to the electrophoresis lane. The amount of protein loaded in each electrophoresis lane must be consistent (usually 20μg). First, perform electrophoresis at a voltage of 80V for 30-40min, then the voltage is maintained at 90V when the sample is in the upper concentrated gel stage, and after entering the separation gel, increase the voltage to 120V. The electrophoresis time depends on the experimental situation.

[0107] b) Transfer: Prepare the required filter paper, PVDF membrane (activated with anhydrous methanol before the experiment) and other related consumables, clamp them in the order of "blackboard-filter paper-protein gel-PVDF membrane-filter paper-white board" and install them in the transfer electrophoresis tank, add an appropriate amount of transfer buffer, and transfer the membrane at a constant current of 300mA for 2h. Remember to add ice boxes to maintain low temperature conditions.

[0108] c) Block with 5% skim milk / TBST at room temperature for 1h, wash the membrane 3 times with 1×TBST, cut the membrane according to the molecular weight of the target protein, and then place it in the corresponding primary antibody diluent and incubate overnight at 4°C. The next day, wash the membrane 3 times with 1×TBST, 10min / time. Then incubate with 5% skim milk containing secondary antibody at room temperature for 1h, and wash the membrane again with 1×TBST 3 times, 10min / time. Pay attention to the shaking speed during the washing process, which should not be too fast or too slow. The primary antibodies are as follows: anti-GAPDH (Santa Cruz, sc-365062), anti-SREBP2 (ImmunoWay, YN0037) (for monkey samples), anti-SREBP2 (Abcam, ab30682) (for human samples).

[0109] d) Exposure and imaging were performed using a Bio-Rad gel imager.

[0110] The results are as follows Figure 6 As shown, the left figure is the experimental result figure, and the right figure is the quantitative statistical figure of the expression level of the activated form of SREBP2 protein; in the left figure, YM1-YM4 and YF1-YF4, OM1-OM4 and OF1-OF4 represent the changes in young and old groups of crab-eating macaques, respectively. It can be seen that the expression level of the activated form of SREBP2 protein in the liver of old crab-eating macaques is increased compared with that in the liver of young crab-eating macaques.

[0111] The above results indicate that the SREBP2 gene or SREBP2 protein is a potential molecular marker for liver aging or hepatocyte aging, and serves as a molecular marker for aging of the liver or liver cells of primates or humans. The degree of aging of the liver or liver cells of primates or humans with low expression of the SREBP2 gene or SREBP2 protein is lower than that of the liver or liver cells of primates or humans with high expression of the SREBP2 gene or SREBP2 protein. The degree of aging is specifically the age of the primate, or the age of the primate or human from which the liver or liver cells are derived, or the age of the human, and the older the age, the higher the degree of aging.

[0112] The nucleotide sequence of the SREBP2 gene is sequence 1;

[0113] The amino acid sequence of SREBP2 protein is sequence 2.

[0114] Example 3: Application of SREBP2, a molecular marker of aging hepatocytes

[0115] 1. Evaluation of the functional status of human hepatocytes after overexpression of SREBP2

[0116] 1. Fluorescence quantitative PCR detection

[0117] Human hepatocytes overexpressing SREBP2 (referred to as SREBP2 overexpression group in the figure) are cells obtained by introducing a lentivirus expressing SREBP2 into human primary hepatocytes;

[0118] The human hepatocytes in the control group (referred to as the control group in the figure) were obtained by introducing a lentivirus expressing a luciferase reporter gene into human primary hepatocytes;

[0119] Each of the above-mentioned lentiviruses is to package each vector into a host cell to obtain a lentivirus, as follows:

[0120] The vector expressing SREBP2 is a plasmid obtained by inserting the SREBP2 gene (sequence 1) between the BamH1 and Mlu1 restriction sites of the pLE4 vector (Bi S, Liu Z, Wu Z, Wang Z, Liu X, Wang S, Ren J, Yao Y, Zhang W, Song M, Liu GH, Qu J. SIRT7 antagonizes human stem cell aging as a heterochromatin stabilizer. Protein Cell. 2020 Jul; 11(7): 483-504. doi: 10.1007 / s13238-020-00728-4. Epub 2020 Jun 6. PMID: 32504224; PMCID: PMC7305295.).

[0121] The vector expressing the luciferase reporter gene is a plasmid obtained by inserting the luciferase reporter gene shown in Sequence 3 between the BamH1 and Mlu1 restriction sites of the pLE4 vector.

[0122] Steps for packaging lentivirus expressing SREBP2:

[0123] 1) Solution A preparation: 1.5mL opti-MEM, 25μL lipo3000. Solution B preparation: 1.5mL opti-MEM, 25μL P3000, 9μg target plasmid (vector expressing SREBP2 or vector expressing luciferase reporter gene), 6μg psPAX2 plasmid (Addgene#12260), 3μg pMD2G plasmid (Addgene#12259). Mix the two and let stand for 15 minutes before use.

[0124] 2) When the HEK293T cells cultured in a 10 cm culture dish grow to 80%-90% density, start lentiviral packaging, mix the above mixture with the cell culture medium, change the cell medium, and culture in a 37°C incubator. Replace with fresh culture medium after 6 hours. Collect the supernatant at 24h and 48h respectively.

[0125] 3) Remove cell debris by centrifugation, filter again with a filter, and then centrifuge at 4°C, 19400 rpm for 2h 15min. Discard the supernatant, add an appropriate amount of Opti-MEM, and thoroughly pipette and store at -80°C to obtain a lentivirus expressing SREBP2 or a lentivirus expressing a luciferase reporter gene.

[0126] The genomic DNA of the human hepatocytes overexpressing SREBP2 and the human hepatocytes of the control group were extracted and amplified according to the method of step 1 of step 2 in Example 2, and the other steps remained unchanged. The expression of genes related to hepatocyte function was detected.

[0127] The human primers are as follows:

[0128] SREBP2 forward(human)AACGGTCATTCACCCAGGTC

[0129] SREBP2 reverse(human)GGCTGAAGAATAGGAGTGTGCC

[0130] CYP1A2 forward(human)CTTCGTAAACCAGTGGCAGG

[0131] CYP1A2 reverse(human)AGGGCTTGTTAATGGCAGTG

[0132] APOC3 forward(human)GAAGCACGCCACCAAGAC

[0133] APOC3 reverse(human)CAGGGTCCAAATCCCAGAA

[0134] UGT2B7 forward(human)AAGGTGCTGGTGGTGGGCAG

[0135] UGT2B7 reverse(human)AGCGGATGAGTGTTGGGA

[0136] CAR forward(human)GTGCTCCTGTGCGGAGTAG

[0137] CAR reverse(human)ATGGCAGATAGGCAGTTTCCC

[0138] Results Figure 7 As shown, it can be seen that the expression levels of genes related to hepatocyte function in human hepatocytes are reduced after overexpression of SREBP2, indicating that the functional state of hepatocytes is impaired.

[0139] 2. Senescence-associated β-galactosidase (SA-β-gal) staining

[0140] 1) Fixative solution preparation: 20mL 37% paraformaldehyde, 1.6mL glutaraldehyde, 378.4mL PBS, mix well and store at 4℃ in the dark. Staining solution preparation: 4mL pH=6.0 citric acid / sodium phosphate buffer, 1mL K3[Fe(CN)6], 1mL K4[Fe(CN)6]·3H2O, 0.04mL MgCl2, 0.6mL NaCl, 1mL X-gal, 12.4mL ddH2O. Mix well and filter, store in the dark, prepare before use.

[0141] 2) Operation steps: Take out human hepatocytes overexpressing SREBP2 as experimental cells (referred to as SREBP2 overexpression group in the figure), discard the culture medium and wash 3 times with PBS, fix the cells at room temperature for 4min 30s. Wash again with PBS 3 times, add 1mL staining solution to each well of the 12-well plate, and incubate at 37℃ in the dark. After staining to the appropriate degree, discard the staining solution, wash 3 times with PBS, and take pictures under a microscope. The human hepatocytes in the control group were used as the control (referred to as the control group in the figure).

[0142] The results are as follows Figure 8As shown, the left figure is a representative figure of the staining results, and the right figure is a statistical result of the percentage of SA-β-gal positive cells; it shows that the expression of SA-β-gal increases in human hepatocytes overexpressing SREBP2, and human hepatocytes show a trend of aging.

[0143] The above results indicate that SREBP2 promotes hepatocyte senescence, and detecting its expression can assess the senescence trend of hepatocytes or the impairment of hepatocyte functional status. Hepatocytes overexpressing SREBP2 can be used as a liver aging model.

Claims

1. Use of a substance for detecting the expression of SREBP2 protein or its encoding gene in any of the following: a1) Preparation of products for assessing or assisting in assessing the degree of liver aging; a2) preparing products for evaluating or assisting in evaluating the degree of hepatocyte senescence; a3) Preparation of products that assess or assist in assessing the functional status of hepatocytes; a4) preparing products that differentiate or assist in differentiating between senescent hepatocytes and young hepatocytes; a5) Preparation of products for evaluating or assisting in the evaluation of liver aging-related diseases, hepatocyte aging-related diseases, or age-related liver diseases.

2. The use according to claim 1, characterized in that: The substance for detecting the expression of SREBP2 protein or its encoding gene is a substance that specifically binds to SREBP2 protein or its encoding gene.

3. Use of SREBP2 gene or protein as a marker in any of the following: a1) Prepare or develop products that assess or assist in assessing the degree of liver aging; a2) Prepare or develop products that assess or assist in assessing the degree of hepatocyte senescence; a3) Prepare or develop products that assess or assist in assessing the functional status of hepatocytes; a4) Prepare or develop products that differentiate or assist in differentiating between senescent hepatocytes and young hepatocytes; a5) Prepare or develop products for evaluating or assisting in the evaluation of liver aging-related diseases, hepatocellular aging-related diseases, or age-related liver diseases.

4. A kit comprising the substance for detecting the expression of SREBP2 protein or its encoding gene as described in claim 1 or 2; The kit has any of the following functions: b1) Assess or assist in assessing the degree of liver aging; b2) Evaluate or assist in evaluating the degree of hepatocyte senescence; b3) Evaluate or assist in evaluating the functional status of hepatocytes; b4) distinguishing or assisting in distinguishing senescent hepatocytes from young hepatocytes; b5) Evaluate or assist in the evaluation of liver aging-related diseases, hepatocellular aging-related diseases, or age-related liver diseases.

5. Use of SREBP2 gene or SREBP2 protein in any of the following: c1) Preparation of products that promote or induce liver aging; c2) preparing products that promote or induce hepatocyte senescence; c3) Preparation of products that promote or induce liver cell function damage; c4) preparing products that promote liver damage.

6. Use of SREBP2 gene or SREBP2 protein in any of the following: d1) Application in the preparation of animal models of liver aging; d2) Application in the preparation of animal models of hepatocyte aging; d3) Application in the preparation of animal models of hepatocyte function damage.

7. A method for preparing an animal model of hepatocyte aging or hepatocyte functional damage, comprising the following steps: introducing SREBP2 gene into animal cells to obtain an animal model of hepatocyte aging or hepatocyte functional damage.

8. The use according to any one of claims 1 to 3 or claims 5 or 6 or the kit according to claim 4 or the method according to claim 7, characterized in that: The liver is derived from animals or humans; The hepatocytes are derived from animals or humans; Furthermore, the hepatocytes are derived from primates.